Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find the highest safe dose of Iodine-131 Tositumomab
(Bexxar®) that can be given to patients who have relapsed/refractory Hodgkin's lymphoma, what
side effects these patients get when they take Bexxar® and if Bexxar® is effective in
treating relapsed/refractory Hodgkin's lymphoma. Bexxar® works by delivering doses of
radiation to cancer cells.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins